{
    "clinical_study": {
        "@rank": "78987", 
        "acronym": "SOARS-B", 
        "arm_group": [
            {
                "arm_group_label": "Placebo Nasal Spray", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }, 
            {
                "arm_group_label": "Oxytocin Nasal Spray", 
                "arm_group_type": "Active Comparator", 
                "description": "Oxytocin"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this research study is to learn about the effects of intranasal oxytocin as a\n      supplemental treatment for improving social difficulties in children and adolescents with\n      autism. This study will also provide additional information about the safety and\n      tolerability of intranasal oxytocin. Investigators expect oxytocin will increase social\n      motivation, improving daily living skills and quality of life."
        }, 
        "brief_title": "Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Autism Spectrum Disorders", 
        "condition_browse": {
            "mesh_term": [
                "Autistic Disorder", 
                "Child Development Disorders, Pervasive"
            ]
        }, 
        "detailed_description": {
            "textblock": "There is a tremendous unmet need for accessible treatments that address core symptoms of ASD\n      and are safe for sustained use. The Study of Oxytocin in ASD to improve Reciprocal Social\n      Behaviors or (SOARS-B) will test a very promising potential treatment\u2212intranasal\n      oxytocin\u2212for ASD's fundamental social communication deficits in a large, group of verbal and\n      nonverbal children.  SOARS-B will also provide information about the regulation of DNA\n      methylation and transcription of the oxytocin receptor gene (OXTR), as well as other genes\n      relevant to oxytocin's CNS activity, as a function of time and in response to oxytocin\n      treatment. These data will fill a key gap in our understanding of oxytocin's role in ASD and\n      its ability to alter epigenetic modifications of the OXTR."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be between the ages of 3 years 0 months and 17  years 11 months at the time of\n             randomization\n\n          -  Be diagnosed by clinician experienced in assessment of ASD with autistic disorder,\n             Asperger's syndrome, or PDD-NOS using DSM-V-TR criteria\n\n          -  Must have clinical diagnosis of ASD confirmed using the Autism Diagnostic\n             Observation Scale (ADOS, Lord et al., 2001)\n\n          -  Must have clinical diagnosis of ASD confirmed using the Autism Diagnostic\n             Interview-Revised (ADI-R, Rutter, 2003). ASD criteria proposed by Risi (2006).\n             Specifically, subject must be within 1 point of autism criteria on both social and\n             communication domains of the ADI or meet autism criteria in one of these ADI domains\n             and come within 2 points of autism criteria in the other\n\n          -  Have a guardian who is able to provide informed consent\n\n          -  If cognitively able, subject must be able to provide informed assent/consent\n\n        Exclusion Criteria:\n\n          -  Have a known diagnosis of Rett Syndrome or Childhood Disintegrative Disorder, or have\n             marked sensory impairment such as deafness or blindness\n\n          -  Have active cardiovascular disease or renal disease that is not controlled by\n             medication\n\n          -  Subjects who are pregnant, lactating, or who refuse to practice contraception if\n             sexually active\n\n          -  Subjects who have had changes in allied health therapies, behavioral or educational\n             interventions within the two months prior to randomization other than those\n             associated with school holidays\n\n          -  Subjects who have had changes in medications or medication doses of   risperidone,\n             aripiprazole, other antipsychotic medications, clonidine, guanfacine, stimulants or\n             anti-convulsants within four weeks of randomization\n\n          -  Subjects who have had previous chronic treatment with oxytocin\n\n          -  Subjects who are currently being treated with an agent that affects brain serotonin\n             levels, including St. John's Wort\n\n          -  Subjects who use benzodiazepines on a regular basis (i.e. 3 of 7 days in a week)\n\n          -  Subjects who have caretakers who are unable to speak English, be consistently present\n             at visits to report on symptoms, or are otherwise judged as unable to comply with the\n             protocol by the data collection site team"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01944046", 
            "org_study_id": "13-0593"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo Nasal Spray", 
                "intervention_name": "Placebo Nasal Spray", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }, 
            {
                "arm_group_label": "Oxytocin Nasal Spray", 
                "description": "Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and months 1 and 2  until achieving the target dose of 24 IU BID at Month 2. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.", 
                "intervention_name": "Oxytocin Nasal Spray", 
                "intervention_type": "Drug", 
                "other_name": "Intranasal Oxytocin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Oxytocin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "autism, ASD, autistic, Asperger's, PDD-NOS, oxytocin", 
        "lastchanged_date": "December 17, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Lurie Center for Autism, Massachusetts General Hospital"
                }, 
                "investigator": {
                    "last_name": "Christopher McDougle, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Alexander Kolevzon, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }, 
                    "name": "Mount Sinai School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Alexander Kolevzon, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27517"
                    }, 
                    "name": "The University of North Carolina at Chapel Hill, Department of Psychiatry"
                }, 
                "investigator": {
                    "last_name": "Linmarie Sikich, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University , Genetics Center"
                }, 
                "investigator": {
                    "last_name": "Simon Gregory, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37212"
                    }, 
                    "name": "Vanderbilt University"
                }, 
                "investigator": [
                    {
                        "last_name": "Jeremy Veenstra-VanderWeele, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Zachary Warren, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98105"
                    }, 
                    "name": "Seattle Children's Hospital Research Institute"
                }, 
                "investigator": {
                    "last_name": "Bryan King, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors", 
        "other_outcome": [
            {
                "description": "Investigators will obtain blood, urine and vital signs from participants at regular intervals in order to assess the safety of oxytocin.  In addition,the blood samples will also be used to assess oxytocin levels, OTXR differential methylation status and to assess mRNA expression.  Investigators will obtain saliva at the same time points to perform salivary oxytocin levels.", 
                "measure": "Changes in Biologic Outcome Measures", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline-2-6-8-12-18 months"
            }, 
            {
                "description": "The Clinical Global Impressions - Improvement score and Severity score, which is routinely used in pharmacologic clinical trials, will capture the study physician's global impression of response.", 
                "measure": "Change in CGI-S and analysis in improvement score (CGI-I)", 
                "safety_issue": "No", 
                "time_frame": "Baseline-18 months inclusive"
            }, 
            {
                "description": "This computerized task consists of a series of pictures of eyes in which the participant needs to determine which emotion the eyes are expressing.", 
                "measure": "Reading Mind in the Eyes Test (change from baseline and/or previous month)", 
                "safety_issue": "No", 
                "time_frame": "Baseline-2-6-8-12-18 months"
            }, 
            {
                "description": "Childhood Anxiety Sensitivity Index (CASI): This scale is designed for measuring anxiety sensitivity (i.e., the belief that anxiety symptoms have negative consequence", 
                "measure": "Change in CASI from previous month", 
                "safety_issue": "No", 
                "time_frame": "Baseline-18 months inclusive"
            }, 
            {
                "description": "Systematic elicitation and screening of adverse events will be completed using the SLAES.", 
                "measure": "Change in Systematic Longitudinal Adverse Events Scale (SLAES)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline-18 months inclusive"
            }
        ], 
        "overall_contact": {
            "email": "aspire@unc.edu", 
            "last_name": "Lindsey M Hazzard, LCSW", 
            "phone": "1-800-708-0048"
        }, 
        "overall_contact_backup": {
            "email": "aspire@unc.edu", 
            "last_name": "Cheryl O Alderman, BS", 
            "phone": "1-800-708-0048"
        }, 
        "overall_official": {
            "affiliation": "University of North Carolina, Chapel Hill", 
            "last_name": "Linmarie Sikich, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The primary outcome is reciprocal social behaviors, which will be assessed using two co-primary measures.  The first measure is the ABC-SW subscale, which is being used in other clinical trials focusing on the core social and communication symptoms of autism.", 
                "measure": "Change in ABC-SW subscale--Reciprocal Social Behavior", 
                "safety_issue": "No", 
                "time_frame": "Baseline- 2-4-6-8-10-12 -18 months"
            }, 
            {
                "description": "The other primary measure is the Sociability Factor (SF), a combined measure derived from 13 items of  the ABC-SW, which primarily captures aloof, and avoidant behaviors, and the Pervasive Developmental Disorders Behavior Inventory-Screening Version (PDDBI-SV).", 
                "measure": "Change in Sociability Factor (SF)", 
                "safety_issue": "No", 
                "time_frame": "Baseline-2-4-6-8-10-12-18"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01944046"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of North Carolina, Chapel Hill", 
            "investigator_full_name": "Linmarie Sikich, MD", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Social Responsiveness Scale (SRS)-Social Motivation subscale, was developed to provide a quantitative measure of social impairments typically observed in ASD in children 3-18 years.", 
                "measure": "Change in SRS-Social Motivation Subscale", 
                "safety_issue": "No", 
                "time_frame": "Baseline-3-6-9-12-18 months"
            }, 
            {
                "description": "Cognitive skills will be assessed using the Stanford Binet-5th Edition (SB-5) (Roid).  If a participant cannot complete the routing tests on the SB-5, they will be assessed using the Mullen.", 
                "measure": "Change in Stanford Binet-5th Edition (SB-5)/Mullen", 
                "safety_issue": "No", 
                "time_frame": "Baseline-6-12-18 months"
            }, 
            {
                "description": "Functional skills including communication will be assessed using the standard score of the Vineland 2 adaptive behavior composite and all its subscales.", 
                "measure": "Change in Vineland II Adaptive Behavior Composite and all its subscales", 
                "safety_issue": "No", 
                "time_frame": "Baseline-3-6-9-12-18 months"
            }, 
            {
                "measure": "Change in Caregiver Strain Questionnaire total and subscale scores", 
                "safety_issue": "No", 
                "time_frame": "Baseline-6-12-18 months"
            }, 
            {
                "description": "This UNC created form asks parents to rate how frequently their child has the opportunity to interact with different individuals in the community, home, school and daycare/after-school setting. It also asks, of those opportunities that their child has, does their child actually utilize those opportunities to interact with individuals in a social manner.", 
                "measure": "Change in Social Opportunity (Questionaire)", 
                "safety_issue": "No", 
                "time_frame": "Baseline-18 months inclusive"
            }
        ], 
        "source": "University of North Carolina, Chapel Hill", 
        "sponsors": {
            "collaborator": {
                "agency": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of North Carolina, Chapel Hill", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}